A federal judge in West Virginia denied Regeneron's request for an injunction against Amgen's Pavblu, creating uncertainty around Eylea's U.S. market exclusivity. At the time, Leerink's Risinger ...

Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, April 1st. Leerink Partnrs analyst D.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

Regeneron stock jumped Thursday ... High-dose Eylea came in at $200 million, beating expectations for $189 million, Leerink Partners analyst David Risinger said in a report.

Analysts at Leerink agreed with Sanofi that, despite falling short of statistical significance in the Phase II TIDE-Asthma trial, amlitelimab warrants further development in this indication.

Research analysts at Leerink Partnrs dropped their FY2026 earnings per share estimates for Alnylam Pharmaceuticals in a ...

In a report released on March 2, David Risinger from Leerink Partners maintained a ... AnaptysBio, and Regeneron. According to TipRanks, Risinger has an average return of 10.3% and a 56.15% ...

Leerink Partners analyst Michael Cherny reiterated a Hold rating on Certara (CERT – Research Report) on April 11. The company’s shares closed last Friday at $12.91. Discover outperforming ...